[HTML][HTML] SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
S Pilz, V Theiler-Schwetz, C Trummer, R Krause… - Environmental …, 2022 - Elsevier
Seroprevalence surveys suggest that more than a third and possibly more than half of the
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …
SARS-CoV-2-specific immune response and the pathogenesis of COVID-19
E Gusev, A Sarapultsev, L Solomatina… - International journal of …, 2022 - mdpi.com
The review aims to consolidate research findings on the molecular mechanisms and
virulence and pathogenicity characteristics of coronavirus disease (COVID-19) causative …
virulence and pathogenicity characteristics of coronavirus disease (COVID-19) causative …
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
LJ Abu-Raddad, H Chemaitelly… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273
(Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic …
(Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic …
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study …
VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk… - The Lancet, 2021 - thelancet.com
Background Increased understanding of whether individuals who have recovered from
COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We …
COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We …
Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons
Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …
England Journal of Medicine Skip to main content The New England Journal of Medicine …
Severity of SARS-CoV-2 reinfections as compared with primary infections
LJ Abu-Raddad, H Chemaitelly… - New England Journal of …, 2021 - Mass Medical Soc
Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
[HTML][HTML] Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a
global pandemic, and cases continue to rise. Most infected individuals experience mildly …
global pandemic, and cases continue to rise. Most infected individuals experience mildly …
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …
central to long-term control of the current pandemic. Despite our rapidly advancing …